Clinical Trial: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Dedifferentiated Liposarcoma
Study Type: INTERVENTIONAL
Official Title: A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma
Brief Summary:
Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced).In addition, their DDLS either has come back after treatment (recurrent), has spread to different parts of your body (metastatic), or is unable to be removed surgically (unresectable).The purpose of this study is to find out whether the combination of etrumadenant and zimberelimab is an effective treatment for people with advanced DDLS.
Read more